Gene expression profile of protein kinases reveals a distinctive signature in chronic lymphocytic leukemia and in vitro experiments support a role of second generation protein kinase inhibitors

[Guest guest]

Gene expression profile of protein kinases reveals a distinctive signature in

chronic lymphocytic leukemia and in vitro experiments support a role of second

generation protein kinase inhibitors.

S Tavolaro, S Chiaretti, M Messina, N Peragine, I Del Giudice, M Marinelli, S

Santangelo, FR Mauro, A Guarini, and R Foa

Leuk Res, December 23, 2009; .

Division of Hematology, Department of Cellular Biotechnologies and Hematology,

" Sapienza " University of Rome, Via Benevento 6, 00161 Rome, Italy.

To investigate the role of protein kinases (PKs) in chronic lymphocytic leukemia

(CLL), we performed gene expression profile on 505 PK genes. Comparison between

CLL with acute lymphocytic leukemia (ALL) patients highlighted an homogeneous

up-modulation of several PKs in CLL, 16 also overexpressed in two additional CLL

cohorts. Q-PCR analysis confirmed these findings. No differences were observed

in the main prognostic subclasses, indicating that PK overexpression is specific

of the disease itself. Tests in vitro showed that Dasatinib partially reduced

CLL cells viability, mostly in IGHV germline patients. These findings suggest

that treatment with second generation tyrosine kinase (TK) inhibitors may

represent an attractive therapeutic strategy for CLL patients.

PMID: 20036005

----------

No virus found in this outgoing message.

Checked by AVG - www.avg.com

Version: 8.5.435 / Virus Database: 271.1.1/2685 - Release Date: 02/13/10

08:43:00